Liquid biopsy moving to early cancer detection: is it still early times?
Despite the promises shown by some innovative technologies in the studies presented, they will not replace existing diagnostic modalities soon
New FGFR inhibitors show potential for the treatment of cholangiocarcinoma
Two early studies investigate the anticancer activity of derazantinib and RLY-4008 in patients with FGFR inhibitor-naïve cholangiocarcinoma
Pathogenic variants in HRR genes can be a risk factor for anthracycline-induced cardiotoxicity
A study presented at ESMO Congress 2022 highlights the need to identify predictors of anticancer drug toxicity as more complex treatments become available
A transcriptomic signature can identify gemcitabine-sensitive patients with pancreatic cancer
Disease-free and overall survival in the PRODIGE-24/CCTG PA6 study were significantly higher in GemPred-positive versus GemPred-negative patients who received adjuvant gemcitabine
Are we getting closer to apply AI-based techniques in clinical practice?
AI technology is being tested across tumour types and with different purposes, with an emerging trend for adding value to whole slide image analyses for HER2 status
Data from two prospective, randomised phase III trials give new insights into the treatment of pancreatic cancer
Survival benefit from the combination of gemcitabine with paclitaxel and the role of patients’ stratification for FOLFORINOX are investigated in metastatic and locally advanced settings
Has TIL therapy the potential to change cancer treatment?
After TILs have shown benefits in advanced melanoma, many ‘synthetic biology’ strategies can be conceived to potentially extend this clinical signal to other patient groups
Lack of clinical benefit with adjuvant canakinumab in completely resected NSCLC
Negative results from the CANOPY-A trial do not support use in the adjuvant setting
PRO data support the use of antibody–drug conjugates in metastatic breast cancer
Patient-reported data from the DESTINY-BREAST04 and TROPiCS-02 trials may help improve current knowledge of quality of life on long-term treatment
First positive phase III data for a gamma secretase inhibitor in desmoid tumours
Nirogacestat improves progression-free survival in a randomised trial performed in desmoid tumours